At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 36 enrolled
Drug / intervention
Acthardrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label Study to Assess the Efficacy and Safety of Acthar® Gel in Subjects With Severe Keratitis
In Brief
A Phase 4 clinical trial evaluating Acthar for Keratitis. Completed, enrolled 36 participants across 9 sites.
Detailed Summary
We will need about 36 participants for this study. Volunteers might be able to participate if: * they have bad noninfectious keratitis * early treatments failed or were not well tolerated Participants will be in the study for about 22 weeks: * 4 weeks for tests to see if the study might be good for them * 12 weeks of treatment with Acthar gel * 4 weeks to wean off Acthar gel and follow-up with the doctor
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKeratitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
Enrollment StartNov 2019
First PostedNov 2019
Primary CompletionNov 2020
Study CompletionDec 2020
TodayJul 2026
First PostedNov 19, 2019
Enrollment StartNov 13, 2019
Primary CompletionNov 9, 2020
Study CompletionDec 7, 2020
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 6.6 years ago
Interventions
Acthardrug
Acthar gel for subcutaneous injection